NCT02954874 2026-03-17
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
3 trialsNCT05333874 2026-02-09
CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage
Rutgers, The State University of New Jersey
Phase EARLY_PHASE1 Active not recruiting
NCT00080756 2024-08-28
Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease
City of Hope Medical Center
Phase 2 Active not recruiting